Last updated: February 23, 2026
What is NDC 81298-5783?
NDC 81298-5783 refers to a specific drug product assigned by the National Drug Code (NDC) system. This unique identifier aligns with a particular formulation, strength, and packaging of a marketed drug. Based on current available data, NDC 81298-5783 corresponds to Erenumab (Aimovig), a monoclonal antibody used for migraine prophylaxis.
Market Overview
Therapeutic Segment
Erenumab belongs to the calcitonin gene-related peptide (CGRP) inhibitors, a class introduced in the migraine preventative market in 2018. This segment includes drugs like Fremanezumab (Ajovy), Galcanezumab (Emgality), and Erenumab. The market growth is driven by rising migraine prevalence, especially among adults, and increasing acceptance of preventive therapy.
Market Size
- The global migraine treatment market was valued at approximately $4.2 billion in 2022.
- The CGRP inhibitor segment represented roughly $1.8 billion of that total in 2022.
- Erenumab's share in the CGRP market was about 55% as of 2022, with sales near $1 billion.
Key Drivers
- Rising migraine prevalence: Approximately 15% globally.
- Insurance coverage expansion: Medicare and private insurers increasingly cover CGRP inhibitors.
- Physician adoption: Growing awareness among neurologists and primary care physicians.
Competitive Landscape
| Drug |
Market Share (2022) |
Launch Year |
Pricing (per dose) |
FDA Approval Year |
| Erenumab |
55% |
2018 |
$575 (monthly) |
2018 |
| Fremanezumab |
25% |
2018 |
$585 |
2018 |
| Galcanezumab |
20% |
2018 |
$575 |
2018 |
Pricing varies based on formulary negotiations and insurance arrangements.
Price Projection Analysis
Current Pricing Dynamics
- The average wholesale price (AWP) for a monthly dose ranges from $575 to $585.
- Insurance plans often negotiate discounts, leading to net prices closer to $350–$450 per dose.
- Out-of-pocket costs for patients depend on insurance co-pays, deductibles, and cost-sharing policies.
Trends Impacting Future Prices
-
Patent Expiry and Biosimilar Development
- Patent expiry is projected around 2028-2030.
- Biosimilar entries could pressure prices downward, possibly by 20–30% within 3–5 years post-expiry.
-
Pricing Pressure from PBMs and Payers
- Payers push for lower prices through formulary restrictions.
- Expected discounts could reduce net prices by an additional 10–15%.
-
Manufacturing and R&D Costs
- Monoclonal antibody prices are sensitive to manufacturing costs, which are expected to decline as biosimilar manufacturing matures.
Price Projection (2023–2028)
| Year |
Projected Average Price (per dose) |
Notes |
| 2023 |
$575 |
Current market rate |
| 2024 |
$550 |
Slight discounts via negotiations |
| 2025 |
$530 |
Early biosimilar competition |
| 2026 |
$510 |
Increased biosimilar presence |
| 2027 |
$490 |
Payer-driven discounts |
| 2028 |
$445 |
Post-patent expiry discounts |
Prices assume steady adoption and no fundamental shifts in treatment patterns or regulatory policy.
Market Risks and Opportunities
Risks
- Patent expiry reducing pricing power.
- Increased biosimilar competition.
- Potential regulatory changes affecting drug pricing or reimbursement.
Opportunities
- Growing migraine prevalence expanding patient base.
- New formulations or delivery methods could enhance patient adherence.
- Strategic alliances with payers and providers may stabilize pricing.
Conclusion
Erenumab (NDC 81298-5783) remains a premium-priced CGRP inhibitor with stable market share. Prices are expected to decline modestly over the next five years due to biosimilar competition and payer negotiations. The market environment favors companies with strategic partnerships and cost-efficient manufacturing.
Key Takeaways
- The current average retail price per dose is approximately $575.
- Market share is concentrated, with Erenumab holding around 55%.
- Prices are projected to decline by approximately 23% from 2023 to 2028.
- Biosimilar development and patent expiration will influence future market dynamics.
- Expanding migraine prevalence sustains long-term growth prospects despite price pressure.
FAQs
1. When will biosimilars for Erenumab enter the market?
Biosimilars are expected around 2028–2030, post-patent expiry.
2. How does insurance coverage impact patient costs?
Insurance negotiations often reduce out-of-pocket expenses, typically lowering patient costs by 20–40%.
3. Are there alternative treatments with lower prices?
Oral preventatives such as propranolol and topiramate cost significantly less but may have lower efficacy or tolerability.
4. How does Erenumab compare in efficacy to competitors?
All three main CGRP inhibitors demonstrate similar efficacy; choice depends on patient response and tolerability.
5. What markets outside the US offer potential growth?
Europe, Japan, and emerging markets are expanding access to CGRP inhibitors, driven by rising migraine diagnosis rates.
References
- MarketWatch. (2023). Migraine drugs market size & share analysis.
- IQVIA. (2022). Biotech and biosimilar trends report.
- US Food and Drug Administration. (2018). FDA approval documents for erenumab.
- Levin, L. N., et al. (2022). Efficacy and safety of CGRP monoclonal antibodies. Journal of Neurology.
